+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diabetic Retinopathy Market - Global Forecast 2026-2032- Product Image
Diabetic Retinopathy Market - Global Forecast 2026-2032- Product Image
New

Diabetic Retinopathy Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 185 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5788863
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The diabetic retinopathy market continues to transform at the intersection of clinical urgency and technological advancement, driven by evolving healthcare demands and the imperative for integrated, patient-centered solutions. Senior decision-makers navigating this space require insights on innovation pathways, stakeholder collaboration, and operational strategies to balance rapid market evolution with optimal patient outcomes.

Market Snapshot: Diabetic Retinopathy Market Size and Growth

The diabetic retinopathy market expanded from USD 9.62 billion in 2025 to USD 10.21 billion in 2026 and is projected to reach USD 14.87 billion by 2032, growing at a CAGR of 6.41%. Growth is propelled by rising diabetes prevalence, expanding pharmaceutical and device offerings, and increased emphasis on early detection and coordinated care.

Scope & Segmentation of the Diabetic Retinopathy Market

  • Product Types: Anti-VEGF agents, corticosteroids, laser equipment, surgical implants
  • Drug Options within Anti-VEGF: Aflibercept, Bevacizumab, Ranibizumab
  • Corticosteroid Variants: Dexamethasone, Triamcinolone
  • Disease Segments: Non-proliferative diabetic retinopathy, proliferative diabetic retinopathy
  • Patient Populations: Adult and pediatric
  • End-User Settings: Ambulatory surgical centers, clinics (general and specialty), hospitals (public and private)
  • Technologies: Retinal imaging, advanced analytics, teleophthalmology, device miniaturization
  • Regions: Americas, Europe, Middle East & Africa, Asia-Pacific

Key Takeaways for Senior Decision-Makers

  • Seamless integration of therapeutic innovation and care delivery is essential to address the clinical complexity of diabetic retinopathy and close gaps in patient access.
  • New pharmacologic and device solutions are changing treatment intervals, influencing clinic workflows and reducing the overall treatment burden on both patients and providers.
  • Advanced diagnostics and analytics are supporting tailored, early intervention strategies and enabling efficient triage between primary and specialist care.
  • Regional market adoption is being influenced by local reimbursement frameworks, infrastructure differences, and the availability of specialist capacity—requiring differentiated go-to-market strategies.
  • Stakeholder alignment on clinical evidence, operational feasibility, and value demonstration is critical for accelerating provider adoption and payer engagement.
  • Real-world data collection and collaborative care models are becoming vital for demonstrating outcomes that resonate with providers, payers, and regulatory authorities.

Tariff Impact on Supply Chain and Commercial Strategies

Recent shifts in tariff policies directly influence procurement decisions, pricing, and supply chain resilience for diabetic retinopathy therapies and devices. Stakeholders must evaluate the effects of tariffs on key imports, such as imaging hardware and surgical components, along with pharmaceutical intermediates. Adjusting sourcing strategies, fostering local manufacturing partnerships, and renegotiating contracts with distributors can help mitigate the impact of elevated import duties, ensuring sustained access and manageable costs.

Methodology & Data Sources

The analysis combines structured clinician interviews, anonymous hospital administrator surveys, and thematic evaluation of peer-reviewed literature. Scenario analysis and triangulation methods were used to confirm data consistency and to examine the operational implications of clinical and policy changes. External clinical advisors validated key assumptions underlying stakeholder-specific insights.

Why This Report Matters for Business Leaders

  • Enables effective alignment of innovation investments with operational realities and reimbursement structures.
  • Offers guidance on regional differentiation and population-tailored clinical pathways to support commercial success.
  • Equips decision-makers with actionable intelligence for supply chain diversification, partnership development, and regulatory navigation.

Conclusion

Diabetic retinopathy presents a pivotal opportunity for integrated clinical advancement and commercial optimization. Leaders leveraging cross-functional strategies and validated insights will be best positioned to accelerate market access and deliver measurable improvements in patient care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Diabetic Retinopathy Market, by Product Type
8.1. Anti-VEGF Agents
8.1.1. Aflibercept
8.1.2. Bevacizumab
8.1.3. Ranibizumab
8.2. Corticosteroids
8.2.1. Dexamethasone
8.2.2. Triamcinolone
8.3. Laser Equipment
8.4. Surgical Implants
9. Diabetic Retinopathy Market, by Diabetic Type
9.1. Non-Proliferative Diabetic Retinopathy
9.2. Proliferative Diabetic Retinopathy
10. Diabetic Retinopathy Market, by Patient Type
10.1. Adult
10.2. Pediatric
11. Diabetic Retinopathy Market, by End-User
11.1. Ambulatory Surgical Centers
11.2. Clinics
11.2.1. General Clinics
11.2.2. Specialty Clinics
11.3. Hospitals
11.3.1. Private Hospitals
11.3.2. Public Hospitals
12. Diabetic Retinopathy Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Diabetic Retinopathy Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Diabetic Retinopathy Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Diabetic Retinopathy Market
16. China Diabetic Retinopathy Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. AbbVie Inc.
17.6. AEYE Health
17.7. Amgen Inc.
17.8. ANI Pharmaceuticals, Inc.
17.9. Bausch + Lomb Corporation
17.10. Bayer AG
17.11. BCN Peptides, S.A.U.
17.12. Boehringer Ingelheim International GmbH
17.13. Clearside Biomedical, Inc.
17.14. Eli Lilly and Company
17.15. Eyenuk, Inc.
17.16. EyePoint Pharmaceuticals, Inc.
17.17. F. Hoffmann-La Roche AG
17.18. Kodiak Sciences Inc.
17.19. Novartis AG
17.20. Ocugen, Inc.
17.21. Ocular Therapeutix, Inc.
17.22. Ocuphire Pharma, Inc.
17.23. OcuTerra Therapeutics
17.24. Opthea Limited
17.25. Oxurion NV
17.26. Pfizer, Inc.
17.27. Regeneron Pharmaceuticals, Inc.
17.28. REGENXBIO Inc.
17.29. RetinaRisk
17.30. RETMARKER
17.31. Samsung Biologics Co., Ltd.
List of Figures
FIGURE 1. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL DIABETIC RETINOPATHY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL DIABETIC RETINOPATHY MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA DIABETIC RETINOPATHY MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DEXAMETHASONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DEXAMETHASONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DEXAMETHASONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TRIAMCINOLONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TRIAMCINOLONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY TRIAMCINOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY LASER EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY LASER EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY LASER EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SURGICAL IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SURGICAL IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SURGICAL IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY NON-PROLIFERATIVE DIABETIC RETINOPATHY, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY NON-PROLIFERATIVE DIABETIC RETINOPATHY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY NON-PROLIFERATIVE DIABETIC RETINOPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PROLIFERATIVE DIABETIC RETINOPATHY, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PROLIFERATIVE DIABETIC RETINOPATHY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PROLIFERATIVE DIABETIC RETINOPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY GENERAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY GENERAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 72. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2032 (USD MILLION)
TABLE 76. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 77. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 97. LATIN AMERICA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2032 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 107. EUROPE DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. EUROPE DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 109. EUROPE DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 110. EUROPE DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 111. EUROPE DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2032 (USD MILLION)
TABLE 112. EUROPE DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 113. EUROPE DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 114. EUROPE DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 115. EUROPE DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 119. MIDDLE EAST DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 120. MIDDLE EAST DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2032 (USD MILLION)
TABLE 121. MIDDLE EAST DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 122. MIDDLE EAST DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 123. MIDDLE EAST DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 124. MIDDLE EAST DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 125. AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 127. AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 128. AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 129. AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2032 (USD MILLION)
TABLE 130. AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 131. AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 132. AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 133. AFRICA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 134. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 144. ASEAN DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 145. ASEAN DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 146. ASEAN DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 147. ASEAN DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 148. ASEAN DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2032 (USD MILLION)
TABLE 149. ASEAN DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 150. ASEAN DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 151. ASEAN DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 152. ASEAN DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 153. GCC DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. GCC DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 155. GCC DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 156. GCC DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 157. GCC DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2032 (USD MILLION)
TABLE 158. GCC DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 159. GCC DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 160. GCC DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 161. GCC DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 162. EUROPEAN UNION DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. EUROPEAN UNION DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 164. EUROPEAN UNION DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 165. EUROPEAN UNION DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 166. EUROPEAN UNION DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 171. BRICS DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. BRICS DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 173. BRICS DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 174. BRICS DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 175. BRICS DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2032 (USD MILLION)
TABLE 176. BRICS DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 177. BRICS DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 178. BRICS DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 179. BRICS DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 180. G7 DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. G7 DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 182. G7 DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 183. G7 DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 184. G7 DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2032 (USD MILLION)
TABLE 185. G7 DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 186. G7 DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 187. G7 DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 188. G7 DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 189. NATO DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. NATO DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 191. NATO DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 192. NATO DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 193. NATO DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2032 (USD MILLION)
TABLE 194. NATO DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 195. NATO DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 196. NATO DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 197. NATO DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 198. GLOBAL DIABETIC RETINOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 199. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 200. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 201. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 202. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 203. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2032 (USD MILLION)
TABLE 204. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 205. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 206. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 207. UNITED STATES DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 208. CHINA DIABETIC RETINOPATHY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 209. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 210. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY ANTI-VEGF AGENTS, 2018-2032 (USD MILLION)
TABLE 211. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 212. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY DIABETIC TYPE, 2018-2032 (USD MILLION)
TABLE 213. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 214. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 215. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 216. CHINA DIABETIC RETINOPATHY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Diabetic Retinopathy market report include:
  • AbbVie Inc.
  • AEYE Health
  • Amgen Inc.
  • ANI Pharmaceuticals, Inc.
  • Bausch + Lomb Corporation
  • Bayer AG
  • BCN Peptides, S.A.U.
  • Boehringer Ingelheim International GmbH
  • Clearside Biomedical, Inc.
  • Eli Lilly and Company
  • Eyenuk, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche AG
  • Kodiak Sciences Inc.
  • Novartis AG
  • Ocugen, Inc.
  • Ocular Therapeutix, Inc.
  • Ocuphire Pharma, Inc.
  • OcuTerra Therapeutics
  • Opthea Limited
  • Oxurion NV
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • REGENXBIO Inc.
  • RetinaRisk
  • RETMARKER
  • Samsung Biologics Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages185
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 10.21 Billion
Forecasted Market Value ( USD ) by 2032 $ 14.87 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Diabetic Retinopathy Treatment Market Size Analysis Report - Market Share, Forecast Trends and Outlook (2025-2034) - Product Image

Diabetic Retinopathy Treatment Market Size Analysis Report - Market Share, Forecast Trends and Outlook (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Non-Proliferative Diabetic Retinopathy Market Report 2025 - Product Image

Non-Proliferative Diabetic Retinopathy Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Diabetic Retinopathy Market Report 2025 - Product Image

Diabetic Retinopathy Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Diabetic Retinopathy Treatment - Global Strategic Business Report - Product Image

Diabetic Retinopathy Treatment - Global Strategic Business Report

  • Report
  • 273 Pages
  • Global
From
Proliferative Diabetic Retinopathy (Pdr) Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Proliferative Diabetic Retinopathy (Pdr) Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From

About the Market

Diabetic Retinopathy (DR) is a medical condition that affects the eyes of people with diabetes. It is caused by damage to the blood vessels in the retina, the light-sensitive layer of tissue at the back of the eye. DR can lead to vision loss and blindness if left untreated. Optical imaging technologies, such as optical coherence tomography (OCT) and fundus photography, are used to diagnose and monitor DR. These technologies allow for early detection and treatment of DR, which can help to reduce the risk of vision loss. In addition to imaging technologies, there are a number of treatments available for DR, including laser photocoagulation, intravitreal injections, and vitrectomy. These treatments can help to reduce the risk of vision loss and improve vision in those with DR. The DR market is a rapidly growing market, driven by the increasing prevalence of diabetes and the need for early detection and treatment of DR. Companies in the DR market include Carl Zeiss Meditec, Topcon Corporation, Optos, Nidek, and Heidelberg Engineering. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.